EuropeResearch and clinical trials
Gitelman syndrome data on 587 patients from Europe: fatigue and salt craving stand out
Data were collected on 587 patients with Gitelman syndrome from 13 countries in Europe.
Kidney diseases
An inherited disease that disturbs the kidney's work of taking back salt. Potassium and magnesium in the blood are low. There may be muscle cramps, tiredness and a craving for salt.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
This page is translated from the Turkish original.
This disease is followed through the “Kidney diseases” group.
The kidneys take salt from the urine back into the blood. In Gitelman syndrome this work cannot be done fully. Salt is lost in the urine. Along with it, the balance of potassium, magnesium and calcium is also disturbed. Symptoms usually begin in late childhood or the teenage years.
Symptoms can differ greatly even within the same family. In most people the course is mild.
The doctor first rules out more common causes of low potassium. A blood test shows low potassium and magnesium. A urine test shows low calcium and high potassium. A genetic test confirms the diagnosis.
The disease is lifelong. For now there is no definite cure, but care reduces the symptoms. The aim is to keep the salt balance in the blood. Most people take potassium and magnesium supplements every day. A diet high in salt and rich in potassium may be advised. A kidney specialist follows the person with regular blood tests. The doctor who follows the disease decides which treatment is suitable.
Gitelman syndrome is passed on through recessive inheritance. Two changed genes are needed to have the disease; one comes from the mother and one from the father. Carrier parents usually have no symptoms. For a carrier couple, the chance of an affected child in each pregnancy is 1 in 4. In marriages between relatives, the chance of two carriers coming together may be higher. Genetic counselling explains the risks to the family.
Source: MedlinePlus Genetics: Gitelman syndrome · NORD: Gitelman Syndrome · Orphanet: Gitelman syndrome (ORPHA:358)
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
We could not find a patient association specific to this disease.
For all rare diseases: Nadir Hastalıklar Federasyonu
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
EuropeResearch and clinical trials
Data were collected on 587 patients with Gitelman syndrome from 13 countries in Europe.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
ClinicalTrials.gov currently lists no active interventional studies for this disease. Last checked: October 7, 2026.
See all studies on ClinicalTrials.gov · Joining clinical trials
TürkiyeDiagnosis and screening
At Ankara University, 63 adults with kidney disease of unknown cause underwent genetic testing.
TürkiyeResearch and clinical trials
Eye doctors at Başkent University studied the eyes of 34 patients with Alport syndrome.
TürkiyeResearch and clinical trials
At Marmara University, 17 children diagnosed with ARPKD were studied.
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:358
No separate ICD-11 code; WHO classifies this disease under: 5C64.41
Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.